文章目录

正电子发射断层扫描研究抗癌药物耐药性的潜力

The potential of positron-emission tomography to study anticancer-drug resistance

原文发布日期：2004-06-01

DOI: 10.1038/nrc1368

类型: Review Article

开放获取: 否

要点：

要点翻译：

英文摘要：

摘要翻译：

原文链接：

文章：

正电子发射断层扫描研究抗癌药物耐药性的潜力

The potential of positron-emission tomography to study anticancer-drug resistance

原文发布日期：2004-06-01

DOI: 10.1038/nrc1368

类型: Review Article

开放获取: 否

要点：

Positron-emission tomography (PET) is a sensitive method for imaging cellular and molecular processes in humans.
PET is a quantitative tool that can measure picomolar levels of drugs and ligands.
PET can be used to image processes involved in resistance and responses to anticancer drugs, such as pharmacokinetics and metabolism, angiogenesis, hypoxia, proliferation, apoptosis and DNA repair.
Spatial, temporal and functional information can be provided using PET.
Studies of mechanisms of resistance to the widely used anticancer agent 5-fluorouracil using PET illustrate the potential of this technique.
To avoid the high rate of attrition from initial drug development to regulatory approval, the ability of PET to image anticancer-drug resistance pathways should be exploited in proof-of-concept studies at an early stage of drug development.
Validation of new imaging probes requires multidisciplinary collaboration involving those working in PET, oncology, tumour-cell and molecular biology, and anticancer-drug discovery, and requires development within both academia and the pharmaceutical industry.

要点翻译：

正电子发射断层扫描（PET）是一种用于对人体细胞与分子过程进行成像的敏感技术。
PET作为一种定量工具，能够检测皮摩尔水平的药物和配体浓度。
该技术可对抗癌药物耐药性与应答相关过程进行成像，包括药代动力学与代谢、血管生成、缺氧状态、细胞增殖、凋亡及DNA修复。
PET能够提供空间、时间及功能信息。
通过对广泛使用的抗癌药物5-氟尿嘧啶的耐药机制进行PET研究，证明了该技术的应用潜力。
为降低从药物研发初期到获批上市过程中的高淘汰率，应在药物开发早期阶段的概念验证研究中充分利用PET对抗癌药物耐药通路的成像能力。
新型成像探针的验证需要多学科协作，涵盖PET技术、肿瘤学、肿瘤细胞与分子生物学以及抗癌药物研发领域的研究者，并需在学术界与制药工业界共同推进发展。

英文摘要：

Positron-emission tomography (PET) is a powerful tool for imaging and quantifying cellular and molecular processes in humans. It has enormous potential to increase our understanding of the pathophysiology of human tumours and to support the development of anticancer drugs. The ability of PET to image mechanisms of anticancer-drug resistance in vivo should be exploited in proof-of-concept studies at early stages of drug development.